Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
Schiller
GLOBETECH PUBLISHING LLC

MRI Guidance Used in Brain Cancer Drug Injection Procedure

By Medimaging International staff writers
Posted on 19 Aug 2013
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Neurosurgeons in California are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors. Using MRI navigational technology, neurosurgeons can inject Toca 511 (vocimagene amiretrorepvec), a unique investigational gene therapy, directly into a brain tumor. This new application offers a precise way to deliver a therapeutic virus designed to make the tumor vulnerable to cancer-killing drugs.

“With chemotherapy, just about every human cell is exposed to the drug’s potential side-effects. By using the direct injection approach, we believe we can limit the presence of the active drug to just the brain tumor and nowhere else in the body,” said Clark Chen, MD, PhD, chief of stereotactic and radiosurgery and vice-chairman of neurosurgery University of California (UC) San Diego School of Medicine (USA). “With MRI, we can see the tumor light up in real time during drug infusion. The rest of the brain remains unaffected so the risk of the procedure is minimized.”

Toca 511 is a retrovirus engineered to selectively replicate in cancer cells, such as glioblastomas. Toca 511 generates an enzyme that converts an antifungal drug, flucytosine (5-FC), into the anticancer drug 5-fluorouracil (5-FU). After the injection of Toca 511, the patients are treated with an investigational extended-release oral formulation of 5-FC called Toca FC. Cancer cell killing takes place when 5-FC comes into contact with cells infected with Toca 511.

“Inevitably, almost all glioblastoma patients fail currently available therapy. The challenge, in part, is knowing if current drugs are actually penetrating the tumor. This MRI-guided approach will help us deliver this drug into the tumor directly to see if the drug is working,” said Santosh Kesari, MD, PhD, lead investigator and director of neuro-oncology at UC San Diego Moores Cancer Center (USA). “This approach may lead to new treatment options for patients battling several other types of brain cancers.”

Earlier research using gene therapy to treat brain cancer was mostly limited by the failure in delivering the drug into the brain. Under normal conditions, the brain is protected by the blood-brain barrier but this natural defense mechanism also prevents drugs from reaching the cancer cells in patients with brain tumors. Fortunately, 5-FC crosses the blood-brain barrier, and direct injection of Toca 511 into the tumor provides a means to selectively generate chemotherapy within the tumor mass.

To ensure that the adequate amount of Toca 511 is delivered to the region of the tumor, neurosurgeons at UC San Diego Health System utilize state-of-the art MRI guidance, called ClearPoint, to track the delivery and injection processes in real time. The MRI-guided process provides visual validation that the desired amount of drug is delivered into the tumor and provides physicians the ability to make adjustments to optimize the location of drug delivery. The Clearpoint technology was developed by MRI Interventions (Memphis, TN, USA).

Participants in this clinical trial must be 18 years or older; have a single, recurrent Grade 3 or 4 glioma; and have had prior surgery, radiation, and chemotherapy. The MRI-based procedure is minimally invasive and all participants of the study were discharged from the hospital one day after surgery and resumed their normal daily activity.

The phase 1 trial is evaluating the safety and tolerability of Toca 511 in combination with Toca FC (5-FC, extended-release tablets), and is being developed by Tocagen, Inc. (San Diego, CA, USA).

Related Links:

University of California, San Diego Moores Cancer Center
Tocagen
MRI Interventions



Channels

Radiography

view channel

New Patient-Centered Tool Devised to Record Side Effects of Radiotherapy

Researchers have investigated a patient-centered approach to evaluating the side effects of radiotherapy and have shown that it may be able to optimize the detection and management of treatment-related toxicity. For lung tumors that cannot be removed with surgery, radiotherapy is the best treatment option.... Read more

Ultrasound

view channel

Guidelines Released for Quantitative Monitoring of Critically Ill and Surgery Patients Using Echocardiography

The American Society of Echocardiography (ASE; Morrisville, NC, USA) has published clinical guidelines describing how and when echocardiography can be used for medical and surgical therapy in adult patients. The guidelines were published in the January 2015 issue of the American Society of Echocardiography.... Read more

Nuclear medicine

view channel
Image: Created by averaging PET scan data from chronic pain patients (left) and healthy controls (right), the images reveal higher levels of inflammation-associated translocator protein (orange/red) in the thalamus and other brain regions of chronic pain patients (Photo courtesy of Marco Loggia, Martinos Center for Biomedical Imaging, Massachusetts General Hospital).

PET/MR Imaging Shows First Evidence of Neuroinflammation in Chronic Pain Patients’ Brains

For the first time, researchers have used neuroimaging strategies to find evidence of neuroinflammation in major regions of the brains of patients with chronic pain. By showing that levels of an i... Read more

General/Advanced Imaging

view channel
Image: Dr. Miles was part of the team that helped identify facial measurements in children with autism that may lead to a screening tool for young children and provide clues to its genetic causes (Photo courtesy of Rebecca F. Miller).

Advanced 3D Facial Imaging Designed to Help in Early Identification of Autism

Autism is a range of closely related disorders observed in patients who exhibit a shared assortment of symptoms, including delays in learning to communicate and interrelate socially. Early detection of... Read more

Imaging IT

view channel

Potential Cost of Data Breaches of Protected Health Information Could Reach USD 5.6 Billion Annually

The healthcare industry and institutions face an ever-increasing threat of data breaches to clinical and patient information. Cybercriminals are attracted to Protected Health Information (PHI) such as Social Security Numbers (SSN) on Medicare cards, and other sensitive medical information stored online on an institutions'... Read more

Industry News

view channel

New Strategic Partnership Agreement for Surgical Displays

An agreement between Barco (Kortrijk, Belgium), a visualization products company, and Medical Computers Deutschland (MCD; Moenchengladbach, Germany), a supplier of customized Healthcare IT (Information Technology) solutions, covers the sale of surgical displays for the healthcare industry in Germany, Austria, and Switzerland.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.